Through magnetic propulsion, the company’s Bionauts can navigate the human body and deliver drugs locally.
Surgical robotics company described share consolidation as the last option to regain compliance with Nasdaq’s $1 per share minimum bid price requirement and retain its listing.
Robotic microsurgery company Medical Microinstruments announced today that it raised $75 million in a Series B financing round.
The latest generation of the Ekso Bionics platform, the EksoNR previously received clearance for stroke and spinal cord rehabilitation in 2016, then acquired brain injury (ABI) in 2020
The Xact Ace system combines image-based procedure planning and real-time monitoring with hands-free precise robotic insertion and non-linear steering.
Worldwide procedures performed with the da Vinci surgical robot increased 19% compared to the fourth quarter of 2020.
Memic’s Hominis system will be used in single-site, natural orifice laparoscopic-assisted transvaginal benign gynecological procedures.
OrthoSpin’s robot-assisted external fixation system for orthopedic treatments is a platform used in DePuy Synthes’ Maxframe.
Medtronic’s rollout of their Hugo robotics assisted surgical robot will be delayed due to supply-chain issues.
Myomo said this is a 128% increase year over year and the highest quarterly revenue in the company’s history.
J&J said the system is being delayed due to technical development challenges and COVID-19-related disruptions, including supply chain constraints.
The CE mark covers urologic and gynecologic procedures, which make up approximately half of all robotic procedures performed today, according to the company.
NuVasive said clinical evaluations for Pulse are now underway across multiple countries throughout Europe.
The procedure marks the beginning of the Hugo system patient registry, which will collect clinical data as Medtronic seeks regulatory submissions.
Memic develops Hominis, the first FDA approved, robotically-assisted surgical device for transvaginal hysterectomies.
Memic Innovative Surgery closed a $96 million Series D financing round. The Tel Aviv, Israel-based company develops Hominis, the first FDA-approved robotically-assisted surgical device for performing transvaginal hysterectomy. The FDA approved the Hominis system last month. Hominis is designed to remove the uterus using minimally invasive surgical instruments inserted through the vagina, as well as…
Forsight Robotics, an Israel-based developer of a robotic surgical platform for ophthalmic procedures, has raised $10 million. The seed round was led by Eclipse Ventures and joined by Mithril Capital. The funding is earmarked to be used for expanding ForSight’s headcount and global reach as it sets its sights on launching its robotic surgery platform…
The U.S. Food and Drug Administration (FDA) authorized marketing for Memic Innovative Surgery’s Hominis system for transvaginal hysterectomy. According to the FDA, Hominis is the first FDA-approved robotically-assisted surgical device for performing transvaginal hysterectomy, with indication for performing benign hysterectomy with salpingo-oophorectomy. Using minimally invasive surgical instruments inserted through the vagina and a video camera…
TransEnterix changed its name to Asensus Surgical and introduced a new category of surgery to its offerings. Research Triangle Park, N.C.-based Asensus Surgical said the name change represents its broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. Sensus is Latin for “cognition,” highlighting the connection…
TransEnterix received CE Mark approval for its Intelligent Surgical Unit for the Senhance system. The Intelligent Surgical Unit (ISU) enables machine vision capabilities on the Senhance surgical system, providing digital laparoscopic programs in Europe to be augmented by intelligence capabilities in surgical settings. The FDA cleared the ISU in March 2020. Research Triangle Park, N.C.-basd…
ReWalk Robotics, a developer of exoskeletons for people with lower-limb disabilities, is seeking to sell nearly 5.6 million ordinary shares, plus more, worth about $6.2 million. Marlborough, Mass.-based ReWalk is also offering more than 4.5 million ordinary shares which are issuable upon the exercise of outstanding warrants, according to a news release. ReWalk is also…
Cerus Endovascular said the groundbreaking intracranial aneurysm procedure was completed with Xcath robotic assistance in just 28 minutes.